These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639 [TBL] [Abstract][Full Text] [Related]
43. [Clinical outcomes and economic analysis of two ovulation induction protocols in patients undergoing repeated IVF/ICSI cycles]. Chen X; Geng L; Li H Nan Fang Yi Ke Da Xue Xue Bao; 2014 Apr; 34(4):563-7. PubMed ID: 24752110 [TBL] [Abstract][Full Text] [Related]
44. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation. Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115 [TBL] [Abstract][Full Text] [Related]
45. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966 [TBL] [Abstract][Full Text] [Related]
46. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection. Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329 [TBL] [Abstract][Full Text] [Related]
47. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger. Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700 [TBL] [Abstract][Full Text] [Related]
48. Effect of the initiation of progesterone supplementation in in vitro fertilization-embryo transfer outcomes: a prospective randomized controlled trial. Gao J; Gu F; Miao BY; Chen MH; Zhou CQ; Xu YW Fertil Steril; 2018 Jan; 109(1):97-103. PubMed ID: 29175065 [TBL] [Abstract][Full Text] [Related]
49. Luteal estrogen supplementation in stimulated cycles may improve the pregnancy rate in patients undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer. Drakakis P; Loutradis D; Vomvolaki E; Stefanidis K; Kiapekou E; Anagnostou E; Anastasiadou K; Milingos S; Antsaklis A Gynecol Endocrinol; 2007 Nov; 23(11):645-52. PubMed ID: 17999276 [TBL] [Abstract][Full Text] [Related]
50. The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles - a randomized controlled study. Moini A; Zadeh Modarress S; Amirchaghmaghi E; Mirghavam N; Khafri S; Reza Akhoond M; Salman Yazdi R Arch Med Sci; 2011 Feb; 7(1):112-6. PubMed ID: 22291742 [TBL] [Abstract][Full Text] [Related]
51. Does the "delayed start" protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial. Ashrafi M; Arabipoor A; Yahyaei A; Zolfaghari Z; Ghaffari F Reprod Biol Endocrinol; 2018 Dec; 16(1):124. PubMed ID: 30593268 [TBL] [Abstract][Full Text] [Related]
52. The effect of administration of intravenous intralipid on pregnancy outcomes in women with implantation failure after IVF/ICSI with non-donor oocytes: A randomised controlled trial. Singh N; Davis AA; Kumar S; Kriplani A Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():45-51. PubMed ID: 31228675 [TBL] [Abstract][Full Text] [Related]
53. The Effect of Coasting on Intracytoplasmic Sperm Injection Outcome in Antagonist and Agonist Cycle. İltemir Duvan ZC; Namlı Kalem M; Onaran Y; Aktepe Keskin E; Ayrım A; Pekel A; Kafalı H; Turhan N Int J Fertil Steril; 2017; 11(1):1-6. PubMed ID: 28367298 [TBL] [Abstract][Full Text] [Related]
54. Route of progesterone administration for luteal phase support may affect outcome of controlled ovarian hyperstimulation for IVF with ICSI using GnRH antagonist. Bahceci M; Ulug U J Assist Reprod Genet; 2008; 25(9-10):499-502. PubMed ID: 18941886 [TBL] [Abstract][Full Text] [Related]
55. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection. Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477 [TBL] [Abstract][Full Text] [Related]
56. Cryopreserved blastocyst transfer: impact of gonadotropin-releasing hormone agonist versus antagonist in the previous oocyte retrieval cycles. Lee JR; Choi YS; Jee BC; Ku SY; Suh CS; Kim KC; Lee WD; Kim SH Fertil Steril; 2007 Nov; 88(5):1344-9. PubMed ID: 17548083 [TBL] [Abstract][Full Text] [Related]
57. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer. Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156 [TBL] [Abstract][Full Text] [Related]
58. Evaluation of the impact of gonadotropin-releasing hormone agonist as an adjuvant in luteal-phase support on IVF outcome. Inamdar DB; Majumdar A J Hum Reprod Sci; 2012 Sep; 5(3):279-84. PubMed ID: 23532169 [TBL] [Abstract][Full Text] [Related]
59. Endometrial scratching in women with implantation failure after a first IVF/ICSI cycle; does it lead to a higher live birth rate? The SCRaTCH study: a randomized controlled trial (NTR 5342). van Hoogenhuijze NE; Torrance HL; Mol F; Laven JSE; Scheenjes E; Traas MAF; Janssen C; Cohlen B; Teklenburg G; de Bruin JP; van Oppenraaij R; Maas JWM; Moll E; Fleischer K; van Hooff MH; de Koning C; Cantineau A; Lambalk CB; Verberg M; Nijs M; Manger AP; van Rumste M; van der Voet LF; Preys-Bosman A; Visser J; Brinkhuis E; den Hartog JE; Sluijmer A; Jansen FW; Hermes W; Bandell ML; Pelinck MJ; van Disseldorp J; van Wely M; Smeenk J; Pieterse QD; Boxmeer JC; Groenewoud ER; Eijkemans MJC; Kasius JC; Broekmans FJM BMC Womens Health; 2017 Jul; 17(1):47. PubMed ID: 28732531 [TBL] [Abstract][Full Text] [Related]
60. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Engmann L; DiLuigi A; Schmidt D; Benadiva C; Maier D; Nulsen J Fertil Steril; 2008 Mar; 89(3):554-61. PubMed ID: 17678651 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]